Pharma Focus Asia

Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Tuesday, August 25, 2020

Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company  announced that it has entered into a strategic collaboration with Vir Biotechnology (Nasdaq: VIR), a clinical-stage immunology company, to discover, develop and commercialize potential novel therapeutic molecules in the fields of Immuno-Oncology and infectious diseases.

HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration. Both parties will then combine their expertise in basic science to accelerate the development of these innovative immunotherapies into the clinic studies for patients suffering from cancers and infectious diseases.

"We are excited to join hands with Vir as both companies share a common mission to serve patients' unmet needs," said Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed. "This collaborative partnership harbors big potential for both companies, as we exploit similar underlying immune mechanisms that likely play a critical role in fighting cancers as well as infectious diseases." 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024